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Abstract
Backgroud: Epstein-Barr virus (EBV) is associated with B-cell lymphoma in various conditions, such as immunodeficiency
and chronic inflammation. We report an unusual case of EBV-positive diffuse large B-cell lymphoma (DLBCL)
lacking the expression of many B-cell markers.
Case presentation: An 83-year-old man presented with a submandibular tumor. Histology of a lymph node
biopsy specimen revealed diffuse proliferation of centroblast- or immunoblast-like lymphoid cells with plasmacytic
differentiation. Scattered Hodgkin/Reed-Sternberg-like cells were also visible. A routine immunohistochemistry antibody
panel revealed that the tumor cells were negative for B-cell and T-cell markers (i.e., CD3, CD19, CD20, CD38, CD45RO,
CD79a, CD138, and Pax-5), but were positive for CD30 and MUM-1, not defining the lineage of tumor cells. The final
diagnosis of EBV-positive DLBCL was confirmed based on the expression of B-cell-specific transcription factors
(Oct-2 and BOB.1), PCR-based identification of monoclonal rearrangement of the immunoglobulin genes, and the
presence of EBV-encoded small RNAs in the tumor cells (identified using in situ hybridization).
Conclusion: The downregulation of broad band of B-cell markers in the present case with EBV-positive DLBCL posed
a diagnostic dilemma, as the possible diagnoses included differentiation from anaplastic large cell lymphoma and
CD20-negative B-cell lymphomas. Results of immunohistochemical panel including B-cell-specific transcription factors
and gene rearrangement analyses critically support the correct diagnosis.
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Background
Epstein-Barr virus (EBV) is associated with the patho-
genesis of several B-cell neoplasms, such as Burkitt
lymphoma, plasmablastic lymphoma (PBL), primary ef-
fusion lymphoma (PEL), immunodeficiency-associated
lymphoproliferative disorders, and some diffuse large
B-cell lymphomas (DLBCL), which include lyphomatoid
granulomatosis and DLBCL with chronic inflammation
[1, 2]. Most EBV-positive B-cell lymphomas, except for
Burkitt lymphoma, develop in cases with systemic im-
munodeficiency or long-standing chronic inflammation,
although B-cell lymphoma can infrequently develop in
the absence of immunodeficiency or inflammatory con-
ditions. These cases typically involve elderly patients,
and some authors have described them as “EBV-posi-
tive DLBCL of the elderly” [3]. Previous studies have
revealed that 2–11% of DLBCL cases are positive for
EBV [4], and these cases are diagnosed based on the
following findings: 1) diffuse infiltration of large lymph-
oid cells, 2) detection of B-cell markers during immu-
nohistochemistry testing (IHC), and 3) the detection of
EBV-encoded small RNAs using in situ hybridization.
In this report, we describe an unusual case of EBV-
positive DLBCL in an immunocompetent patient,
which was difficult to diagnose due to the absence of
many B-cell markers during routine IHC. Our final
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diagnosis was critically supported by the IHC identifica-
tion of B-cell-specific transcription factors (Oct-2 and




An 83-year-old man noticed a left submandibular mass
and visited our Department of Oral Surgery. He had no
B symptoms. His family history was unremarkable, al-
though he had a history of renal insufficiency. A physical
examination revealed an elastic hard tumor (diameter:
4 cm) that was well-demarcated and had not adhered to
the surrounding tissue. The covering skin was normal,
and the patient reported not experiencing spontaneous
pain or tenderness. Laboratory testing revealed slight
anemia (red blood cell count: 385 × 104/μL, hemoglobin
levels: 11.7 g/dL) and leukopenia (white blood cell
count: 3,900/μL), although his serum lactate dehydro-
genase levels were not elevated (207 IU/L). Levels of
soluble interleukin-2 receptor were markedly elevated
(2,730 IU/mL), although we did not detect elevated ti-
ters of antibodies to human T-cell leukemia virus-1 or
human immunodeficiency virus (HIV). Computed tom-
ography and diffusion-weighted magnetic resonance
imaging revealed a left submandibular tumorous lesion
and multiple swollen lymph nodes (the left cervical and
inguinal nodes) (Fig. 1). Magnetic resonance imaging
also revealed multiple high-intensity areas in the verte-
brae, bilateral ribs, and ilia, although there were no
abnormalities in the mediastinum or abdomen. We ob-
tained a biopsy specimen from the submandibular le-
sion, which supported our initial pathological diagnosis
of anaplastic large cell lymphoma (ALCL), although a
hematopathological consultant helped us make a final
diagnosis of EBV-positive DLBCL. The patient under-
went 2 courses of chemotherapy using the THP-COP
regimen and achieved partial remission, although the
tumor was ultimately resistant to the following therap-
ies: molecular-targeted therapy using brentuximab
vedotin, THP-COP (4’-O-tetrahydropyranyl adriamycin,
cyclophosphamide, Oncovin®, prednisolone), and EPOCH
(etoposide, prednisolone, Oncovin®, cyclophosphamide,
hydroxydaunorubicin). The patient was alive with progres-
sive disease at the 9-month follow-up.
Histological evaluation
Hematoxylin-eosin (HE) staining revealed that the
lymph node architecture was effaced and diffusely oc-
cupied by infiltrative large lymphoid cells. Many foci
of necrosis were visible, and the lesion was comprised
of centroblast-like cells (a large vesicular nucleus and
several conspicuous nucleoli), immunoblast-like cells
(prominent central nucleoli), and plasmacytic cells
(Figs. 2 and 3). There were scattered large multinu-
clear cells with prominent nucleoli, including large
cells that were similar to Hodgkin/Reed-Sternberg cells
(HRS-like cells) (Fig. 3).
The initial IHC revealed that the tumor cells were
positive for CD30 and MUM-1, but negative for CD3,
CD4, CD5, CD8, CD10, CD19, CD20, CD23, CD38,
CD45, CD45RO, CD56, CD79a, CD138, Pax-5, immuno-
globulin light chains (κ and λ), epithelial membrane anti-
gen (EMA), anaplastic lymphoma kinase (ALK), Bcl-2,
and Bcl-6 (Fig. 4b-g). These results could not define cell
lineage and histological type of the tumor. Additional
IHC revealed that the tumor cells were positive for B-
cell-specific transcription factors (Oct-2 and BOB.1),
which confirmed B-cell derivation of the tumor cells
(Fig. 4h and i). In situ hybridization revealed clear
Fig. 1 Computed tomography imaging of the tumor. A well-
demarcated tumor is located in the left submandibular region
(coronal plane)
Fig. 2 Low-magnification histological findings from the biopsy
specimen. The lymph node architecture is effaced and occupied
with diffuse infiltrative tumor cells. Foci of necrosis are visible
(hematoxylin and eosin staining, original magnification: ×40)
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positive signals for EBV-encoded small RNAs in the
nuclei of the tumor cells (Fig. 5). The tumor cells
were negative for LANA-1 (a product of human
herpesvirus-8), and the Ki-67 labeling index was very
high (approximately 80%).
Clonality analysis
We performed gene rearrangement testing using the
BIOMED-2 multiplex polymerase chain reaction-based
method, which revealed clonal rearrangement of the im-
munoglobulin heavy chain and light chain genes. No clonal
rearrangement was detected in the T-cell receptor genes.
Fig. 3 High-magnification histological findings from the biopsy
specimen. Diffuse infiltration of large lymphoid cells that are similar
to centroblasts or immunoblasts. Large multinuclear giant cells are
scattered around the necrotic focus (hematoxylin and eosin staining,
magnification: ×100). Hodgkin/Reed-Sternberg-like cells are also
visible (inset)
Fig. 4 Immunohistochemistry findings from the biopsy specimen. Small lymphocytes seen in the upper left of photograph (a) are non-neoplastic
B-cells in a lymph follicle (hematoxylin and eosin staining). The large neoplastic cells are negative for CD20 (b), CD79a (c), CD19 (d), Pax-5 (e), and
CD3 (f), but are positive for CD30 (g), Oct-2 (h), and BOB.1 (I)
Fig. 5 In situ hybridization findings. Most of the tumor cells,
including the Hodgkin/Reed-Sternberg-like cells, exhibited positive
signals for EBV-encoded small RNAs in the nucleus, which suggested
a latent Epstein-Barr virus infection
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Discussion and conclusions
EBV-related lymphomas develop in various conditions,
including systemic immunodeficiency and chronic in-
flammation [1, 2]. Most of these lymphomas are derived
from B-cells, and EBV-positive B-cell lymphomas usually
express several B-cell surface markers, although they oc-
casionally lack one or more markers. However, few stud-
ies have evaluated the frequency of B-cell marker loss in
EBV-positive B-cell lymphomas. One flow cytometry-
based study revealed that 4 of 25 cases (16%) of post-
transplant lymphoproliferative disorder exhibited almost
complete loss of CD20 expression (all 4 CD20-negative
cases were EBV-positive), compared to only 8 of 334
cases (2%) of de novo B-cell non-Hodgkin lymphoma
[5]. Another study revealed a higher incidence of de-
creased CD19 expression in cases of posttransplant lym-
phoproliferative disorder, compared to cases of common
DLBCL (3 of 4 cases [75%] vs. 8 of 56 cases [14%]) [6].
The frequency of CD20-negative tumors among HIV-
positive DLBCL cases is variable (2–26%) [7]. Neverthe-
less, to the best of our knowledge, there are no reported
cases of EBV-positive B-cell lymphoma lacking a broad
range of B-cell markers. McKelvie et al. reported a case
of EBV-positive methotrexate-associated DLBCL that
was negative for CD20 and CD79a [8]. Although that
case and the present case were both positive for CD30
and MUM-1, McKelvie et al.’s case was positive for Pax-
5 and ours was negative for Pax-5.
Our histological findings included the diffuse prolifera-
tion of CD20-negative and CD3-negative large cells in-
cluding immunoblastic cells, plasmacytic cells, and
multinuclear cells, which was compatible with various
differential diagnoses: ALCL, extracavitary PEL, ALK-
positive large B-cell lymphoma (ALK-LBCL), and PBL.
In histology of our case CD30-positive HRS-like cells
appeared, which mimicked ALCL and support our pre-
liminary diagnosis before EBV testing by EBERs in situ
hybridization. However, ALCL is exclusively EBV-
negative and does not exhibit clonal rearrangement of
the immunoglobulin genes. Extracavitary PEL usually
develops in cases of systemic immunodeficiency, such
as HIV infection, and is almost exclusively positive for
human herpesvirus-8. ALK-LBCL is positive for ALK,
CD138, and EMA, but is negative for EBV. Our initial
IHC findings and the subsequent detection of EBV
using EBERs in situ hybridization excluded ALCL,
extracavitary PEL, and ALK-LBCL. PBL is positive for
CD138 in almost all cases and also frequently expresses
CD38 and MUM-1 [9, 10]. Although the results of IHC
of our case could not clearly exclude PBL, diagnosis of
PBL is unlikely because of lack of CD138 and CD38 ex-
pression. MUM-1 is one of markers for plasma cell
differentiation, but previous studies showed that speci-
ficity of MUM-1 as a plasma cell marker is limited [11].
Montes-Moreno et al. categorized tumors with plasma-
blastic morphology and atypical immunophenotype
(CD138 low or positive, CD20 low, Pax-5 low, MUM-1
positive, Blimp1 positive, and XBP1 negative) as PBL
with variant (faulty) plasmablastic phenotype, and our
case might be classified into this category according to
their scheme [12]. Although we were initially unable to
identify the lineage of tumor cells and histological type,
the presence of necrotic foci and HRS-like cells in the
tumor suggested an EBV-related disease, which
prompted us to test for the expression of additional B-
cell markers. Expression of B-cell-specific transcription
factors detected by additional IHC and clonal re-
arrangement of the immunoglobulin genes confirmed
our final diagnosis of EBV-positive DLBCL. Inadequate
IHC using limited surface markers may lead to a mis-
diagnosis in cases of lymphomas with an unusual
immunophenotype. It is important to miss a chance to
perform further IHC in such cases, therefore detailed
histological evaluation and accurate interpretation of
results from a well-designed initial IHC panel are es-
sential for reaching a correct diagnosis.
No previous studies have explained why B-cell markers
are down-regulated in EBV-positive B-cell lymphomas,
and the association of EBV infection with the suppres-
sion of B-cell markers remains unclear. Expression of la-
tent EBV infection products influences the epigenetic
status of the host cells [13], which might be associated
with the regulation of B-cell marker expression. Down-
regulation of CD20 in B-cell neoplasms is often related
to plasmablastic features and terminal B-cell differenti-
ation of the tumor cells [7]. Most CD20-negative B-cell
lymphomas with plasmablastic features are positive for
CD138, whereas tumor of the present case was negative
for CD138. Therefore, plasmablastic features or plasma-
cytic differentiation is insufficient to explain the lack of
these markers of our case. Moreover, the tumor did not
express Pax-5, which is a critical B-cell lineage commit-
ment factor and upregulates the expression of various B-
cell differentiation markers [14]. Thus, it is possible that
down-regulation of Pax-5 or aberrancy of other factors
that modulate Pax-5 might have caused the loss of B-cell
markers in our case. Mutations and translocations that
involve the Pax-5 gene have been reported in some cases
of B-cell lymphoma and leukemia [15–18]. In addition,
the CD20-negative phenotype is observed in 26–27% of
B-cell lymphomas after molecular-targeted therapy using
rituximab [19, 20]. Several mechanisms can cause the
down-regulation of CD20 after rituximab treatment: 1)
mutational changes in the CD20 gene [21, 22], (2) aber-
rant transcriptional regulation of CD20 [23–25], (3)
degradation of the CD20 protein by the ubiquitin-
proteasome system [23], (4) other posttranscriptional
or posttranslational changes in the regulation of CD20,
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and (5) genetic or transcriptional alterations in tran-
scription factors that affect the expression of CD20
(e.g., PU.1 or Oct-2). Therefore, similar abnormalities
involving Pax-5 or other common B-cell derivation fac-
tors may be responsible for the lack of B-cell markers
in our case.
Previous studies have revealed that cases of DLBCL with
reduced CD20 expression experience markedly inferior sur-
vival when they are treated using conventional CHOP
(cyclophosphamide, hydroxydaunorubicin, Oncovin®, pred-
nisolone) or rituximab-CHOP [26, 27]. Furthermore, a
study of CD20-negative DLBCL cases, in which PBL and
ALK-LBCL were carefully excluded, revealed that
CD20-negative cases had a poorer response to conven-
tional treatment and a poorer prognosis, compared to
CD20-positive cases [7]. Moreover, CD20-negative
cases had a higher proportion of the non-germinal cen-
ter B-cell subtype, a higher proliferation index, and
more frequent extranodal involvement, which might
explain the biological aggressiveness of CD20-negative
DLBCL [7].
In conclusion, we encountered an unusual case of EBV-
positive DLBCL that was lacking various B-cell markers.
This type of unusual phenotype often leads to an incorrect
diagnosis, which can only be avoided by detailed evalu-
ation of histopathology and appropriate utility of ancillary
diagnostic tools, such as IHC for lineage-specific markers
and gene rearrangement testing.
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